ID   WM115
AC   CVCL_0040
SY   WM-115; WM 115; WM115F; WM115-mel; WM115mel; WC00079
DR   BTO; BTO:0003075
DR   CLO; CLO_0009613
DR   EFO; EFO_0002390
DR   CLDB; cl4727
DR   CLDB; cl4728
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1675
DR   BioGRID_ORCS_Cell_line; 345
DR   BioSample; SAMN10987773
DR   cancercelllines; CVCL_0040
DR   Cell_Model_Passport; SIDM01000
DR   CGH-DB; 9323-4
DR   ChEMBL-Cells; CHEMBL3308813
DR   ChEMBL-Targets; CHEMBL1075611
DR   Coriell; WC00079
DR   Cosmic; 886835
DR   Cosmic; 888868
DR   Cosmic; 897480
DR   Cosmic; 905236
DR   Cosmic; 909784
DR   Cosmic; 932717
DR   Cosmic; 972277
DR   Cosmic; 1155268
DR   Cosmic; 1155547
DR   Cosmic; 1238102
DR   Cosmic; 1238104
DR   Cosmic-CLP; 909784
DR   DepMap; ACH-000304
DR   ECACC; 91061232
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   ESTDAB; ESTDAB-066
DR   GDSC; 909784
DR   GEO; GSM109022
DR   GEO; GSM827472
DR   GEO; GSM887735
DR   GEO; GSM888830
DR   GEO; GSM1670576
DR   IARC_TP53; 21271
DR   IARC_TP53; 24992
DR   IGRhCellID; WM115
DR   IZSLER; BS TCL 74
DR   LiGeA; CCLE_370
DR   LINCS_HMS; 50567
DR   LINCS_LDP; LCL-1260
DR   Lonza; 584
DR   PharmacoDB; WM115_1662_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0040
DR   PubChem_Cell_line; CVCL_0040
DR   Rockland; WM115-01-0001
DR   Wikidata; Q54994157
RX   PubMed=2253310;
RX   PubMed=3020539;
RX   PubMed=3856042;
RX   PubMed=4053039;
RX   PubMed=11121133;
RX   PubMed=15009714;
RX   PubMed=15467732;
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21424129;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.proteinatlas.org/learn/cellines
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   HLA typing: A*02:01,29:02; B*13:02,44:03:01; C*06:02,16:01; DPB1*02:01:02,02:01:02; DQB1*02:01,02:01; DRB1*07:01,07:01 (PubMed=15592718).
CC   HLA typing: A*02:01,29:02; B*13:02,44:03; C*06:02,16:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (PubMed=15009714; PubMed=15467732; Wistar).
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.17%; East Asian, North=0%; East Asian, South=0%; South Asian=0.85%; European, North=67.47%; European, South=31.51% (PubMed=30894373).
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: CSF1PO: 11,12->12, D18S51: 17->17,21 and D8S1179: 8,13->13,15.
CC   Misspelling: WH115mel; CGH-DB=9323-4.
CC   Discontinued: ATCC; CRL-1675; probable.
CC   Discontinued: Coriell; WC00079; probable.
CC   Discontinued: ECACC; 91061232; probable.
CC   Derived from site: Metastatic; Right anterior leg, skin; UBERON=UBERON_0001511.
ST   Source(s): ATCC; Cosmic-CLP; ESTDAB; Wistar
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12,13
ST   D16S539: 11,12
ST   D18S51: 17,21
ST   D19S433: 13
ST   D21S11: 29
ST   D2S1338: 19
ST   D3S1358: 15,18
ST   D5S818: 13
ST   D7S820: 8
ST   D8S1179: 13,15
ST   FGA: 21,23
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_L033 ! WM165-1
OI   CVCL_RN55 ! WM165-2
OI   CVCL_6795 ! WM239A
OI   CVCL_RN56 ! WM239B
OI   CVCL_RN57 ! WM266-1
OI   CVCL_RN58 ! WM266-2
OI   CVCL_RN59 ! WM266-3
OI   CVCL_2765 ! WM266-4
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 45
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=3020539; DOI=10.1073/pnas.83.19.7197;
RA   Westermark B., Johnsson A., Paulsson Y., Betsholtz C., Heldin C.-H.,
RA   Herlyn M., Rodeck U., Koprowski H.;
RT   "Human melanoma cell lines of primary and metastatic origin express
RT   the genes encoding the chains of platelet-derived growth factor (PDGF)
RT   and produce a PDGF-like growth factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7197-7200(1986).
//
RX   PubMed=3856042; DOI=10.1093/jnci/74.2.283;
RA   Herlyn M., Balaban G.B., Bennicelli J.L., Guerry D. IV, Halaban R.,
RA   Herlyn D., Elder D.E., Maul G.G., Steplewski Z., Nowell P.C.,
RA   Clark W.H. Jr., Koprowski H.;
RT   "Primary melanoma cells of the vertical growth phase: similarities to
RT   metastatic cells.";
RL   J. Natl. Cancer Inst. 74:283-289(1985).
//
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G.B., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H. Jr.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=11121133; DOI=10.1046/j.1523-1747.2000.00199.x;
RA   Lacal P.M., Failla C.M., Pagani E., Odorisio T., Schietroma C.,
RA   Falcinelli S., Zambruno G., D'Atri S.;
RT   "Human melanoma cells secrete and respond to placenta growth factor
RT   and vascular endothelial growth factor.";
RL   J. Invest. Dermatol. 115:1000-1007(2000).
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21424129; DOI=10.3892/or.2011.1220;
RA   Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G.,
RA   Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F.,
RA   Palmieri G.;
RT   "Induction of arginosuccinate synthetase (ASS) expression affects the
RT   antiproliferative activity of arginine deiminase (ADI) in melanoma
RT   cells.";
RL   Oncol. Rep. 25:1495-1502(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//